

### DRAFT PROGRAM of the Vulnerable Patient Meeting

#### (Sunday) June 22, 2014 -Day 1-

16:00 - 16:10	Opening remarks: Board of directors (Prof. Serruys, Prof. Stone, Prof. van der Steen, Prof. Koenig, Prof. Lerman, Dr. García-García and Dr. van Es)
16:10 - 16:15	Welcome remarks: Guest director (Prof. Dorian Haskard)
16:15 - 18:30	Key note lectures: Dorian Haskard and Patrick W. Serruys
16:15 - 16:30	Mega-trials (tbd)
16:30- 16:35	Sir Rory Collins (UK) Q&A
16:35 - 16:50	MRI for coronary plaque characterization, is it ever going to be part of the standard clinical practice? <b>Dudley Pennell (UK)</b>
16:50- 16:55	Q&A
16:55 - 17:10	ApoA-I Milano administration induces plaque regression and stabilisation in the long term  Juan Badimon (USA)
17:10- 17:15	Q&A
17:15 - 17:30	Large multicentre trials on vulnerable patient populations - from ASCOT to the new PCSK9 trials  Peter Sever (UK)
17:30- 17:35	Q&A
17:35 - 17:50	What is the standard of care for vulnerable patients today?  Valentin Fuster (USA)
17:50- 17:55	Q&A
17:55 - 18:10	The role of efferocytosis and apoptosis in Vulnerable Plaque  Ira Tabas (USA)
18:10- 18:15	Q&A
18:15 - 18:45	Discussion

### DRAFT PROGRAM of the Vulnerable Patient Meeting

#### (Monday) June 23, 2014 -Day 2-

08:00 - 08:15	Master lecture: primary prevention of atherothrombotic events in the asymptomatic population Valentin Fuster (USA)
08:15 - 08:30	Discussion
08:30 - 10:00	Early detection of Subclinical Atherosclerosis Initiatives (Part I)
08:30 - 08:40	Screening for Heart Attack Prevention and Education (SHAPE)  Erling Falk (DN)
08:40 - 08:42	Q&A
08:42 - 08:52	HAPPY Global Foundation Leo Hofstra (NL)
08:52 - 08:54	Q&A
08:54 - 09:04	The Program SI! intervention for enhancing a healthy lifestyle in preschoolers and PESA study
	Valentin Fuster (USA)
09:04 - 09:06	Q&A
09:06 - 09:16	Polypill Therapy, Subclinical Atherosclerosis, and Cardiovascular Events – Implications for the Use of Preventive Pharmacotherapy (MESA study)
	Márcio Sommer Bittencourt ( USA)
09:16 - 09:18	Q&A
09:18 - 09:28	CT PROSPECT Udo Hoffmann (USA)
09:28 - 09:30	Q&A
09:30 - 10:00	Discussion
10:00 - 10:50	Coffee break
10:50 - 12:15	Early detection of Subclinical Atherosclerosis Initiatives (Part II)
10:50 - 11:00	Ethical, economical and social considerations about risk profiling  Ken Redekop (NL)
11:00 - 11:02	Q&A
11:02 - 11:12	Point of view of ESC  Alan G. Fraser (UK)
11:12 - 11:15	Q&A
11:15 - 11:25	Increasing subject awareness in primary prevention: models and implementation  Coen v Kalken (NL)
11:25 - 11:27	Q&A
11:27 - 11:37	Remote cardiac telemetry and cardiac remote monitoring
11.2/ 11.0/	Amir Lerman (USA)
11:37 – 11:39	Q&A
11:39 – 12:15	Discussion

### DRAFT PROGRAM of the Vulnerable Patient Meeting

#### (Monday) June 23, 2014 -Day 2-

12:15 - 14:20	Lunch break
14:20 - 16:30	New pathophysiological concepts of coronary atherosclerosis
14:20 - 14:30	Cap buckling as a potential mechanism of atherosclerotic plaque vulnerability <b>Philippe L. L'Allier (CAN)</b>
14:30 - 14:32	Q&A
14:32 - 14:42	Defect in plaque collagen metabolism contributes to the depletion of collager Andrew Newby (UK)
14:42 - 14:44	Q&A
14:44 - 14:54	Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phenotype  Joe Boyle (UK)
14:54 - 14:56	Q&A
14:56 - 15:06	Lipid-lowering therapy with statins reduces microparticle shedding from endothelium, platelets and inflammatory cells  Lina Badimon (SPA)
15:06 - 15:08	Q&A
15:08 - 15:18	Antisense technology and MTTP Inhibitors  Eric Stroes (NL)
15:18 – 15:20	Q&A
15:20 - 15:30	The mitochondria as a therapeutic target in ischemia  Lilach Lerman (USA)
15:30 - 15:32	Q&A
15:32 - 15:42	Experimental models for the investigation of high-density lipoprotein-mediated cholesterol efflux  Juan Badimon (USA)
15:42 - 15:44	Q&A
15:44 - 15:54	Gene expression on endothelial cells – implications for refurbishing the endothelial lining
	Richard Rapoza (USA)
15:54 - 15:56	Q&A
15:56 - 16:30	Discussion
16:30 - 17:10	Coffee break
17:10 - 19:00	Invasive imaging update (PART I)
17:10 - 17:30	OCT for plaque characterization: beyond fibrous cap detection
17:10 - 17:20	Clinical perspective: Carlo di Mario (UK)
17:20 - 17:30	Pathological perspective: Farouc Jaffer (USA)
17:30 - 17:34	Q&A
17:34 - 17:44	High speed OCT
17:34 - 17:44	Clinical perspective: Evelyn Regar (NL)
17:44 - 17:54 17:54 - 17:58	Bioengineer perspective: <b>Gijs van Soest (NL)</b> Q&A



### DRAFT PROGRAM of the Vulnerable Patient Meeting

#### (Monday) June 23, 2014 -Day 2-

17:58 - 18:08	Photoacoustics  Ton van der Steen (NL)
18:08 - 18:10	Q&A
18:10 - 18:20	Is the LCBI a predictor of events?
	David Erlinge (SE)
18:20 - 18:22	Q&A
18:22 - 19:00	Discussion



### DRAFT PROGRAM of the Vulnerable Patient Meeting

#### (Tuesday) June 24, 2014 -Day 3-

08:00 - 08:15	Master lectures: Humoral immunity in atherosclerosis - from mechanisms to biomarkers Dorian Haskard (UK)
08:15 - 08:30	Discussion
<b>08:30 - 09:40</b> 08:30 - 08:40	Molecular imaging of vulnerable plaque Anti-OX LDL imaging
00.00 - 00.40	Ramzi Khamis (UK)
08:40 - 08:42	Q&A
08:42 - 08:52	Gold nanocrystal labelling allows low-density lipoprotein imaging from the subcellular to macroscopic level  Valentin Fuster (Mount Sinai School of Medicine in New York, USA)
08:52 - 08:54	Q&A
08:54 - 09:04	NIRF imaging Farouc Jaffer (Mass General, USA)
09:04 - 09:06	Q&A
09:06 - 09:16	Identifying active microcalcification by PET  David Newby (Edinburgh, Scotland)
09:16 - 09:18	Q&A
09:18 - 09:40	Discussion
09:40 - 10:20	Coffee break
10:20 - 12:00	Invasive imaging update (PART II)
10:20 - 10:30	PROSPECT, VIVA and ATHEROREMO IVUS: Rick Kuntz' maths revisited  Hector Garcia/Patrick W. Serruys (NL)
10:30 - 10:32	Q&A
10:32 - 10:42	A good old friend: IVUS greyscale revisited  Akiko Maehara (USA)
10:12 - 10:44	Q&A
10:44 - 10:54	IBIS 3 final results including biomarkers  Patrick W. Serruys (NL)
10:54 - 10:56	Q&A
11:18 - 11:28	NIRS trials  Jim Goldstein (USA)
11:28 - 11:30	Q&A
11:30 - 12:00	Discussion
12:00 - 12:30	Invasive and non-invasive imaging - Sceptic roundtable Moderator: Gregg Stone (USA) Gregg Stone/Patrick W. Serruys/Jim Muller/Carlo diMario/Ton van der Steen/Akiko Maehara/Hector García-García what the panel believes and doesn't believe.

### DRAFT PROGRAM of the Vulnerable Patient Meeting

#### (Tuesday) June 24, 2014 -Day 3-

12:30 - 14:30	Lunch break
14:30 - 15:30	Experiment Models of Atherosclerosis- Is there ever going to be a model for vulnerable plaque?
14:30 - 14:40	Cloned minipigs created by DNA transposition of a human PCSK9 gain-of- function mutant <i>Erling Falk (DN)</i>
14:40 - 14:42	Q&A
14:42 - 14:52	Porcine models of accelerated coronary atherosclerosis  Robert Wilensky (USA)
14:52 - 14:54	Q&A
14:54 - 15:30	Discussion
15.20 17.20	Harron minorus and a cint athory storage briggs
<b>15:30 - 16:30</b> 15:30 - 15:40	Unmet primary endpoint atherosclerosis trials From IBIS-2 to Stability
	Liz Tarka (USA)/ Patrick W. Serruys (NL)
15:40 - 15:42	Q&A
15:42 - 15:52	CHI-SQUARE & ASSURE studies
15.50 15.54	Philippe L. L'Allier (CAN)
15:52 - 15:54 15:54 - 16:04	Q&A
15:54 - 16:04	Why they did not meet the primary endpoint?  Wolfgang Koenig (GER)
16:04 - 16:06	Q&A
16:06 - 16:30	Discussion
16:30 - 17:00	Coffee break
17:00 - 16:30	New directions on the treatment of atherosclerosis
17:00 - 17:10	Diabetic and obese are a particular type of vulnerable patients
	Lina Badimon (SPA)
17:10 - 17:12	Q&A
17:12 - 17:22	ATHEROREMO Study final results
	Patrick W. Serruys (NL)
17:22 - 17:24	Q&A
17:24 - 17:34	Apo-l Milano
17.24 17.27	David Kallend (CH)
17:34 - 17:36 17:36 - 17:46	Q&A The CANTOS Study (IL-1 β AB)
17.50 - 17.40	Wolfgang Koenig (GER)
17:46 - 17:48	Q&A
17:48 - 17:58	MODIFY trial
	Philippe L. L'Allier (CAN)
17:58 - 18:00	Q&A
18:00 - 18:10	CANARY trial
	Gregg Stone (USA)
18:10 - 18:12	Q&A



#### **DRAFT PROGRAM of the Vulnerable Patient Meeting**

#### (Tuesday) June 24, 2014 -Day 3-

18:12 - 18:22	PROSPECT II: Imaging &Intervention
	Gregg Stone (USA)
18:22 - 18:24	Q&A
18:24 - 18:34	Refurbishing the endoluminal surface of the coronaries: my DREAMS® have always come true <b>Patrick W. Serruys (NL)</b>
18:34 - 18:36	Q&A
18:36 - 18:46	Predicting PROSPECT II results
	John Ambrose
18:46 - 19:15	Discussion

19:15 - 19:30 Closing remarks: Patrick W. Serruys, Amir Lerman, Wolfgang Koenig and Gregg Stone, Gerrit-Anne van Es, Ton van der Steen and Hector García-García

